NeuroSense Therapeutics (NASDAQ:NRSN) Announces Earnings Results

NeuroSense Therapeutics (NASDAQ:NRSN) issued its quarterly earnings results on Wednesday. The company reported ($0.11) earnings per share (EPS) for the quarter, Zacks reports.

NeuroSense Therapeutics Stock Up 3.7 %

NASDAQ NRSN traded up $0.04 during trading hours on Wednesday, hitting $1.13. 409,189 shares of the company were exchanged, compared to its average volume of 264,800. The company has a 50 day moving average of $1.12 and a two-hundred day moving average of $1.03. The firm has a market cap of $15.45 million, a price-to-earnings ratio of -1.32 and a beta of 1.38. NeuroSense Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.33.

Analyst Upgrades and Downgrades

Separately, Maxim Group restated a “hold” rating on shares of NeuroSense Therapeutics in a research note on Monday.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.